FDA re­jects Co­herus' re­worked Neu­las­ta biosim­i­lar due to third-par­ty in­spec­tions

The FDA has re­ject­ed Co­herus Bio­Sciences’ new pre­sen­ta­tion for its Udeny­ca (peg­fil­gras­tim-cbqv) biosim­i­lar due to an in­spec­tion at one of its con­trac­tors.

Co­herus said the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.